- Home
- MTA vs FULC Comparison
MTA vs FULC Comparison
Compare MTA & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | FULC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 718.4M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTA | FULC |
|---|---|---|
| Price | $7.59 | $7.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $16.38 |
| AVG Volume (30 Days) | 447.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $118.89 | N/A |
| Revenue Next Year | $69.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $2.32 |
| 52 Week High | $9.25 | $15.74 |
Technical Indicators
Market Signals| Indicator | MTA | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 33.14 |
| Support Level | $7.32 | $7.40 |
| Resistance Level | $7.73 | $7.64 |
| Average True Range (ATR) | 0.48 | 0.65 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 1.29 | 6.49 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.